Last reviewed · How we verify
Half dose of MVC-COV1901 — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Half dose of MVC-COV1901 (Half dose of MVC-COV1901) — Medigen Vaccine Biologics Corp..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Half dose of MVC-COV1901 TARGET | Half dose of MVC-COV1901 | Medigen Vaccine Biologics Corp. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Half dose of MVC-COV1901 CI watch — RSS
- Half dose of MVC-COV1901 CI watch — Atom
- Half dose of MVC-COV1901 CI watch — JSON
- Half dose of MVC-COV1901 alone — RSS
Cite this brief
Drug Landscape (2026). Half dose of MVC-COV1901 — Competitive Intelligence Brief. https://druglandscape.com/ci/half-dose-of-mvc-cov1901. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab